Linagliptin and metformin hydrochloride

(Jentadueto®)

Jentadueto®

Latest News

loading GIF

Drug updated on 5/17/2024

Dosage FormTablet (oral; linagliptin/ metformin; 2.5 mg /500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg)
Drug ClassDipeptidyl peptidase-4 inhibitors and biguanides
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Linagliptin and metformin hydrochloride (Jentadueto) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • The information comes from a single study, a randomized controlled trial.
  • In the study, Jentadueto was compared with metformin alone. Both were combined with lifestyle changes in patients who have impaired glucose tolerance plus two risk factors for type 2 diabetes.
  • Compared to using only metformin, the combination of linagliptin and metformin showed superior effectiveness in enhancing glucose metabolism, improving pancreatic β-cell function, reducing progression from prediabetes to type 2 diabetes, and increasing chances of achieving normoglycemia.
  • No major side effects were observed during the study for either group, indicating that both treatment regimens are well tolerated by this specific population subgroup.
  • This suggests that Jentadueto might be particularly beneficial for preventing progression to type 2 diabetes among individuals characterized by impaired glucose tolerance along with at least two other risk factors when used alongside lifestyle modifications.

Product Monograph / Prescribing Information

Document TitleYearSource
Jentadueto (linagliptin and metformin hydrochloride) Prescribing Information.2023Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Randomized Controlled Trials

Clinical Practice Guidelines